what this node claims
AlphaFold metrics / FGFR1
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
52%
low debt pressure
21%
74%structureusable
pLDDT 73.84
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 73.84
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 73.84
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
822 residues / min 21.48 / max 98.62 / source alphafold db
Very high
33.5%
275 residues / >=90
Confident
36.3%
298 residues / 70-89
Low
6.9%
57 residues / 50-69
Very low
23.4%
192 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 822 of 822 residues.
- residues 398-464 / mean 33.32
- residues 763-822 / mean 34.13
- residues 120-148 / mean 39.06
- residues 13-39 / mean 38.82
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.